
Opinion|Videos|December 23, 2024
Using Technology for Early Detection of LEMS
A panelist discusses how enhanced screening protocols combined with predictive analytics can accelerate Lambert-Eaton myasthenic syndrome (LEMS) detection in high-risk populations like patients with small cell lung cancer (SCLC) while also exploring the potential of telemedicine to improve early diagnosis in underserved communities.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How can improved screening protocols and the integration of predictive analytics in clinical practice enhance early detection of LEMS in high-risk patients, such as those with SCLC, and which patient populations should be prioritized?
- In what ways can telemedicine and digital health tools support earlier detection of LEMS, especially in underserved areas?
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5


